These observations with the CDX models showed that initial EGFR inhibition significantly delayed the regrowth of ALK-rearranged NSCLC tumors with both rapid and slow recurrences after lorlatinib treatment by accelerating cell apoptosis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.